A detailed history of Norris Perne & French LLP transactions in Novo Nordisk A S stock. As of the latest transaction made, Norris Perne & French LLP holds 2,220 shares of NVO stock, worth $193,961. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,220
Previous 1,574 41.04%
Holding current value
$193,961
Previous $224,000 17.86%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$119.07 - $145.42 $76,919 - $93,941
646 Added 41.04%
2,220 $264,000
Q1 2024

Apr 16, 2024

BUY
$102.11 - $135.92 $160,721 - $213,938
1,574 New
1,574 $202,000
Q3 2021

Oct 26, 2021

SELL
$84.42 - $106.62 $1.13 Million - $1.43 Million
-13,395 Closed
0 $0
Q2 2021

Jul 20, 2021

SELL
$67.66 - $84.76 $25,372 - $31,785
-375 Reduced 2.72%
13,395 $1.12 Million
Q1 2021

Apr 30, 2021

SELL
$67.06 - $75.82 $242,019 - $273,634
-3,609 Reduced 20.77%
13,770 $928,000
Q4 2020

Jan 27, 2021

BUY
$63.89 - $73.8 $25,236 - $29,151
395 Added 2.33%
17,379 $1.21 Million
Q4 2019

Jan 22, 2020

SELL
$49.86 - $58.26 $373,950 - $436,950
-7,500 Reduced 30.63%
16,984 $983,000
Q1 2019

Apr 29, 2019

SELL
$46.36 - $52.63 $96,197 - $109,207
-2,075 Reduced 7.81%
24,484 $1.28 Million
Q4 2018

Jan 28, 2019

SELL
$41.54 - $47.25 $12,295 - $13,986
-296 Reduced 1.1%
26,559 $1.22 Million
Q2 2018

Jul 24, 2018

SELL
$44.29 - $50.42 $296,300 - $337,309
-6,690 Reduced 19.94%
26,855 $1.24 Million
Q4 2017

Jan 23, 2018

SELL
$47.53 - $53.73 $95,060 - $107,460
-2,000 Reduced 5.63%
33,545 $1.8 Million
Q3 2017

Nov 01, 2017

BUY
$41.15 - $49.22 $1.46 Million - $1.75 Million
35,545
35,545 $1.71 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Norris Perne & French LLP Portfolio

Follow Norris Perne & French LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.